Emilio Guillén Mancina

Dr. Emilio Guillén Mancina

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2021 in Plants
Verified
Journal Article
Open access
PDF file
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
SSSara María Martínez Sánchez
Sara María Martínez Sánchez
VJVíctor Jiménez-González
Víctor Jiménez-González
EBEstefanía Burgos
Estefanía Burgos
EMEmilio Guillén Mancina
Emilio Guillén Mancina
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Finding cytotoxic drugs with a high selectivity towards cancer cells is crucial to improve the low survival rates of patients diagnosed with metastatic cancers. Since plants are an important source of anticancer drugs, we have screened 65 extracts from 45 plants collected in several areas of Western Andalusia (Spain) for cytotoxic activity on lung cancer cells versus lung normal cells. An extract from the leaves of Tetraclinis articulata (Vahl) Mast. (Cupressaceae) showed a marked cytotoxicity (IC50 = 0.37 ± 0.03 μg/mL) and selectivity (selectivity index = 378.3) against the lung cancer cells; cisplatin, 5-fluorouracil, and an extract from the leaves of Taxus baccata L. (Taxaceae) were less cytotoxic and selective. Extracts from Cascabela thevetia (L.) Lippold (Apocynaceae), Frangula alnus Mill. (Rhamnaceae), Iberis ciliata subsp. contracta (Pers.) Moreno (Brassicaceae), Juniperus macrocarpa Sm (Cupressaceae), and Pancratium maritimum L. (Amaryllidaceae) also showed selective cytotoxicity (selectivity index > 10). Active extracts were also tested against a panel of cancer cell lines from a variety tissues. The plants identified in this work are potential sources of natural compounds with selective toxicity towards cancer cells.

28 August 2018 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
JJJulio José Jiménez-Alonso
Julio José Jiménez-Alonso
EMEmilio Guillén Mancina
Emilio Guillén Mancina
EBEstefanía Burgos
Estefanía Burgos
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro

Verified
Journal Article
Open access
PDF file
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
EMEmilio Guillén Mancina
Emilio Guillén Mancina
JJJulio José Jiménez-Alonso
Julio José Jiménez-Alonso
VJVíctor Jiménez-González
Víctor Jiménez-González
EBEstefanía Burgos
Estefanía Burgos
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Targeted therapies with antiangiogenic drugs (e.g., sunitinib) and immune checkpoint inhibitors (e.g., anti-PD-1 antibodies) are the standard of care for patients with metastatic renal cell carcinoma. Although these treatments improve patient survival, they are rarely curative. We previously hypothesized that advanced cancers might be treated without drugs by using artificial diets in which the levels of specific amino acids (AAs) are manipulated. In this work, after showing that AA manipulation induces selective anticancer activity in renal cell carcinoma cells in vitro, we screened 18 artificial diets for anticancer activity in a challenging animal model of renal cell carcinoma. The model was established by injecting murine renal cell carcinoma (Renca) cells into the peritoneum of immunocompetent BALB/cAnNRj mice. Mice survival was markedly improved when their normal diet was replaced with our artificial diets. Mice fed a diet lacking six AAs (diet T2) lived longer than mice treated with sunitinib or anti-PD-1 immunotherapy; several animals lived very long or were cured. Controlling the levels of several AAs (e.g., cysteine, methionine, and leucine) and lipids was important for the anticancer activity of the diets. Additional studies are needed to further evaluate the therapeutic potential and mechanism of action of this simple and inexpensive anticancer strategy.

17 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
JJJulio José Jiménez-Alonso
Julio José Jiménez-Alonso
EMEmilio Guillén Mancina
Emilio Guillén Mancina
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
VJVíctor Jiménez-González
Víctor Jiménez-González
PDPatricia Díaz-Ortega
Patricia Díaz-Ortega
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
New therapies are needed to improve the low survival rates of patients with metastatic colon cancer. Evidence suggests that amino acid (AA) restriction can be used to target the altered metabolism of cancer cells. In this work, we evaluated the therapeutic potential of selective AA restriction in colon cancer. After observing anticancer activity in vitro, we prepared several artificial diets and evaluated their anticancer activity in two challenging animal models of metastatic colon cancer. These models were established by injecting CT26.WT murine colon cancer cells in the peritoneum (peritoneal dissemination) or in the tail vein (pulmonary metastases) of immunocompetent BALB/cAnNRj mice. Capecitabine, which is a first-line treatment for patients with metastatic colon cancer, was also evaluated in these models. Mice fed diet TC1 (a diet lacking 10 AAs) and diet TC5 (a diet with 6% casein, 5% glutamine, and 2.5% leucine) lived longer than untreated mice in both models; several mice survived the treatment. Diet TC5 was better than several cycles of capecitabine in both cancer models. Cysteine supplementation blocked the activity of diets TC1 and TC5, but cysteine restriction was not sufficient for activity. Our results indicated that artificial diets based on selective AA restriction have therapeutic potential for colon cancer.

28 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EMEmilio Guillén Mancina
Emilio Guillén Mancina
JJJulio José Jiménez-Alonso
Julio José Jiménez-Alonso
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
VJVíctor Jiménez-González
Víctor Jiménez-González
PDPatricia Díaz-Ortega
Patricia Díaz-Ortega
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Patients with metastatic triple negative breast cancer (TNBC) need new therapies to improve the low survival rates achieved with standard treatments. In this work, we show for the first time that the survival of mice with metastatic TNBC can be markedly increased by replacing their normal diet with artificial diets in which the levels of amino acids (AAs) and lipids are strongly manipulated. After observing selective anticancer activity in vitro, we prepared five artificial diets and evaluated their anticancer activity in a challenging model of metastatic TNBC. The model was established by injecting 4T1 murine TNBC cells into the tail vein of immunocompetent BALB/cAnNRj mice. First-line drugs doxorubicin and capecitabine were also tested in this model. AA manipulation led to modest improvements in mice survival when the levels of lipids were normal. Reducing lipid levels to 1% markedly improved the activity of several diets with different AA content. Some mice fed the artificial diets as monotherapy lived much longer than mice treated with doxorubicin and capecitabine. An artificial diet without 10 non-essential AAs, with reduced levels of essential AAs, and with 1% lipids improved the survival not only of mice with TNBC but also of mice with other types of metastatic cancers.

29 May 2018 in Natural Product Research
Verified
Journal Article
Closed access
JMJOSÉ MANUEL CALDERÓN MONTAÑO
JOSÉ MANUEL CALDERÓN MONTAÑO
SSSara María Martínez Sánchez
Sara María Martínez Sánchez
EBEstefanía Burgos
Estefanía Burgos
EMEmilio Guillén Mancina
Emilio Guillén Mancina
JJJulio José Jiménez-Alonso
Julio José Jiménez-Alonso
MLMiguel Lopez-Lazaro
Miguel Lopez-Lazaro
Since plants are an important source of anticancer drugs, we have carried out a random screening for selective anticancer activity of 57 extracts from 45 plants collected in Grazalema Natural Park, an area in the South of Spain of high plant diversity and endemism. Using lung cancer cells (A549) and lung non-malignant cells (MRC-5), we found that several extracts were more cytotoxic and selective against the cancer cells than the standard anticancer agent cisplatin. Five active extracts were further tested in cancer and normal cell lines from other tissues, including three skin cell lines with increasing degree of malignancy. An extract from the leaves of Daphne laureola L. (Thymelaeaceae) showed a striking potency and selectivity on lung cancer cells and leukemia cells; the IC50 values against these cancer cells were approximately 10,000-fold lower than against the normal cells. Daphnane-type diterpene orthoesters may be responsible for this highly selective anticancer activity.